Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 3,713,937 | 2,248,243 | 1,828,292 | 1,037,418 | 844,287 |
| Cost of Goods | 681,871 | 323,370 | 310,406 | 168,817 | 140,144 |
| Gross Profit | 3,032,066 | 1,924,873 | 1,517,886 | 868,601 | 704,143 |
| Operating Expenses | 2,531,359 | 2,102,128 | 1,800,467 | 1,654,490 | 1,412,939 |
| Operating Income | 501,578 | -176,885 | -282,175 | -785,072 | -708,652 |
| Interest Expense | 252,627 | 141,858 | 121,221 | 155,968 | 143,021 |
| Other Income | 74,201 | -58,632 | -30,121 | -185,953 | -471 |
| Pre-tax Income | 323,152 | -377,375 | -433,517 | -1,126,993 | -852,144 |
| Income Tax | 9,405 | -99,218 | 6,725 | 4,163 | 680 |
| Net Income Continuous | 313,747 | -278,157 | -440,242 | -1,131,156 | -852,824 |
| Net Income | $313,747 | $-278,157 | $-440,242 | $-1,131,156 | $-852,824 |
| EPS Basic Total Ops | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 |
| EPS Basic Continuous Ops | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 |
| EPS Diluted Total Ops | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 |
| EPS Diluted Continuous Ops | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 |
| EPS Diluted Before Non-Recurring Items | N/A | -2.18 | -3.52 | -9.30 | -7.20 |
| EBITDA(a) | $557,236 | $-120,215 | $-228,121 | $-740,604 | $-618,958 |